Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2025-02-11 00:00:00 ET · period of report 2025-02-07 · accession 0001437749-25-003454 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-11 | 2025-02-07 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +198.4K | 7.23M | +3% | $0 |
| D | 2025-02-11 | 2025-02-07 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +274.6K | 274.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-07 | A | A | 198,399 | $0.00 | 7,228,073 | D | — | — | (F1) Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-07 | A | A | 274,622 | $0.00 | 274,622 | D | $2.78 · — to 2035-02-06 | 274,622 Common Stock | (F2) Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events. |